According to Zacks, “Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. “
Several other research analysts also recently issued reports on XENE. Canaccord Genuity reissued a buy rating and set a $16.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, August 5th. Guggenheim began coverage on shares of Xenon Pharmaceuticals in a research report on Monday, September 26th. They set a buy rating and a $20.00 price objective on the stock.
Xenon Pharmaceuticals (NASDAQ:XENE) opened at 8.38 on Thursday. The company’s 50 day moving average is $7.99 and its 200 day moving average is $7.31. The firm’s market cap is $120.89 million. Xenon Pharmaceuticals has a 52-week low of $5.65 and a 52-week high of $9.93.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.06. Xenon Pharmaceuticals had a negative net margin of 199.68% and a negative return on equity of 28.85%. Equities research analysts forecast that Xenon Pharmaceuticals will post ($1.55) EPS for the current fiscal year.
In other news, Director Frank A. Holler sold 18,062 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $7.93, for a total value of $143,231.66. Following the sale, the director now owns 169,006 shares of the company’s stock, valued at $1,340,217.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Frank A. Holler sold 11,938 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $7.65, for a total transaction of $91,325.70. Following the completion of the sale, the director now directly owns 145,869 shares in the company, valued at approximately $1,115,897.85. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Opaleye Management Inc. increased its stake in shares of Xenon Pharmaceuticals by 2.5% in the second quarter. Opaleye Management Inc. now owns 410,000 shares of the biopharmaceutical company’s stock valued at $2,419,000 after buying an additional 10,000 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Xenon Pharmaceuticals by 110.3% in the second quarter. Perceptive Advisors LLC now owns 432,800 shares of the biopharmaceutical company’s stock valued at $2,553,000 after buying an additional 227,000 shares during the last quarter. Finally, BVF Inc. IL increased its stake in shares of Xenon Pharmaceuticals by 57.7% in the first quarter. BVF Inc. IL now owns 1,775,572 shares of the biopharmaceutical company’s stock valued at $12,411,000 after buying an additional 650,000 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.